Conbercept treatment for heart-shaped vascular intertwined nets in macular neovascularization:anti-VEGF drug therapy strategy based on vascular geometry diagnosed by OCTA [PDF]
Clinical Case Reports, Volume 13, Issue 10, October 2025.Macular neovascularization (MNV), a hallmark of several retinal disorders including ocular trauma and wet age-related macular degeneration, remains a major cause of vision impairment due to the proliferation of abnormal, fragile blood vessels.
Cai, Minqing +3 more
core +2 more sources
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects. [PDF]
, 2023 Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related
Blum, Claudine A +7 more
core +4 more sources
Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment-A Meta-Analysis and Systematic Review. [PDF]
, 2023 Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine.
Garweg, Justus G. +3 more
core +1 more source
Frontiers in Pharmacology, 2022 Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous.
Junlan Chuan +10 more
doaj +1 more source
A post hoc Evaluation of Data from the HAWK and HARRIER Trials [PDF]
, 2022 Funding Information: Development of this publication was funded by Novartis Pharma AG including medical writing and editorial assistance. The sponsor participated in data analysis, interpretation of the data, and review of the manuscript.
B, Guruprasad B. +10 more
core +1 more source
Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
Case Reports in Ophthalmology, 2022 This report describes a case of choroidal effusion after intravitreal brolucizumab injection for wet age-related macular degeneration (AMD). A 71-year-old Korean man with a history of wet AMD visited our clinic.
Ha Eun Sim, Jae Suk Kim, Je Hyung Hwang
doaj +1 more source
International Journal of Retina and Vitreous, 2023 Background The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD).
Joseph M. Coney +18 more
doaj +1 more source
KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. [PDF]
, 2023 PURPOSE To report the 100-week outcomes from KESTREL and KITE. DESIGN Two phase 3, double-masked, active-controlled, randomized trials. METHODS Patients with diabetic macular edema (DME) were randomized 1:1:1 to brolucizumab 3 mg/6 mg ...
Agostini, Hansjuergen T +14 more
core +1 more source
Reactions Weekly, 2020 Wie Aflibercept und Ranibizumab hemmt Brolucizumab den «Vascular Endothelial Growth Factor» (VEGF) und kann zur intravitrealen Behandlung der exsudativen (neovaskulären) altersbedingten Makuladegeneration eingesetzt werden. VEGF-Hemmer können zu entzündlichen Augenkomplikationen führen.
+5 more sources
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. [PDF]
, 2022 PURPOSE To compare the efficacy and safety of brolucizumab with aflibercept in patients with diabetic macular edema (DME). DESIGN Double-masked, 100-week, multicenter, active-controlled, randomized trials.
Bandello, Francesco +18 more
core +1 more source